Drugs / CodaVax-H1N1
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05223179 | Apr 2022 → Feb 2024 | influenza | Codagenix, Inc | Completed | No outcome recorded |
| Phase 1 | NCT04146623 | May 2019 → Oct 2020 | influenza | Codagenix, Inc | Completed | No outcome recorded |
| Phase 1 | NCT03926416 | Feb 2017 → May 2018 | influenza | Codagenix, Inc | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CODA-VAX H1N1 | “Intramuscular CodaVax-H1N1 in Healthy Adults” NCT05223179 ↗ |
| Known as | CodaVax-H1N1 influenza vaccine | “This study is being conducted to assess the safety, tolerability, and immunogenicity of the live-attenuated CodaVax-H1N1 influenza vaccine as compared to normal saline placebo...” NCT04146623 ↗ |
| Modality | Vaccine | “live-attenuated vaccine against influenza A H1N1” NCT03926416 ↗ |
| Route | Intranasal | “a single intranasal (IN) dose of CodaVax-H1N1” NCT03926416 ↗ |